ACE Inhibitors and ARBs: First-Line BP Meds, Side Effects, and Kidney Protection

The Renin-Angiotensin-Aldosterone System (RAAS)

The Renin-Angiotensin-Aldosterone System (RAAS) is a primary hormonal cascade that regulates systemic blood pressure, intravascular volume, and sodium balance. When renal perfusion pressure falls, or when sympathetic activity stimulates the kidneys, juxtaglomerular cells secrete the enzyme renin into the bloodstream. Renin cleaves circulating angiotensinogen, produced by the liver, into the inactive decapeptide angiotensin I. Angiotensin-Converting Enzyme (ACE), primarily found in the pulmonary vascular endothelium, then cleaves two amino acids from angiotensin I to form the active octapeptide angiotensin II.

Angiotensin II is a potent vasoconstrictor that binds to Angiotensin II Type 1 (AT1) receptors on vascular smooth muscle, causing arterial constriction and raising systemic vascular resistance. Additionally, angiotensin II stimulates the adrenal cortex to release aldosterone, which acts on the distal nephron to promote sodium reabsorption and water retention, expanding intravascular volume. In the heart and kidneys, chronic exposure to high levels of angiotensin II promotes hypertrophy, inflammation, and fibrotic remodeling. Suppressing this system is a primary target of modern antihypertensive pharmacotherapy.

Mechanisms of Action: ACE Inhibitors vs. ARBs

ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs) target different steps of the RAAS cascade:

• ACE Inhibitors (e.g., Lisinopril, Ramipril, Enalapril): These drugs competitively bind to and inhibit the ACE enzyme. This reduces the production of angiotensin II and decreases the breakdown of bradykinin, a vasodilatory peptide. Increased bradykinin levels promote nitric oxide release, contributing to vasodilation. However, elevated bradykinin in the lungs can stimulate airway sensory fibers, causing the dry, persistent cough characteristic of ACE inhibitor therapy.
• Angiotensin II Receptor Blockers (ARBs) (e.g., Losartan, Valsartan, Olmesartan): These agents selectively bind to and block the AT1 receptor, preventing the actions of angiotensin II. Because ARBs block the receptor directly, they do not inhibit the breakdown of bradykinin. Consequently, ARBs provide similar blood-pressure-lowering and organ-protective benefits as ACE inhibitors but carry a much lower risk of causing a dry cough or angioedema.

Understanding these pharmacological mechanisms helps clinicians manage class-specific side effects and optimize treatment plans.

Renal Protection and Intrglomerular Hemodynamics

Beyond lowering systemic blood pressure, ACE inhibitors and ARBs provide significant protection against the progression of chronic kidney disease (CKD) and diabetic nephropathy. In the kidney, angiotensin II constricts the efferent arteriole (the outflow blood vessel of the glomerulus) more than the afferent arteriole (the inflow vessel). This selective constriction increases pressure within the glomerulus (intraglomerular pressure), leading to hyperfiltration and protein leakage (proteinuria). Over time, chronic hyperfiltration causes glomerular damage and progressive loss of kidney function.

By blocking angiotensin II or its formation, ACE inhibitors and ARBs dilate the efferent arteriole, reducing intraglomerular pressure and hyperfiltration. Clinical trials, such as the RENAAL study (using losartan) and the IDNT study (using irbesartan), have demonstrated that this hemodynamic effect reduces proteinuria and slows the decline of renal function in patients with diabetic nephropathy. Consequently, RAAS blockers are the preferred first-line therapy for hypertensive patients with diabetes, chronic kidney disease, or proteinuria, regardless of their racial background.

Side Effects and Clinical Monitoring

While generally well-tolerated, ACE inhibitors and ARBs require clinical monitoring for potential adverse effects:

• Dry Cough: Occurs in 5% to 20% of patients taking ACE inhibitors, mediated by bradykinin accumulation. It is dry, hacking, and does not respond to cough suppressants. Switching to an ARB resolves the cough.
• Hyperkalemia: By reducing aldosterone secretion, RAAS blockers decrease potassium excretion in the kidneys. Monitoring is required, especially in patients with advanced CKD or those taking potassium supplements.
• Acute Kidney Injury (AKI): Dilation of the efferent arteriole can cause a transient reduction in glomerular filtration rate (GFR). A modest rise in serum creatinine (up to 30% from baseline) is expected and does not require drug discontinuation. However, in patients with bilateral renal artery stenosis, where glomerular filtration is highly dependent on angiotensin II-mediated efferent constriction, RAAS blockade can precipitate acute renal failure.
• Angioedema: A rare but potentially life-threatening adverse effect characterized by swelling of the face, lips, tongue, and airway. It is more common with ACE inhibitors than ARBs and occurs more frequently in Black patients, due to alterations in bradykinin metabolism.

These medications are also contraindicated in pregnancy due to the risk of fetal renal dysgenesis and cardiovascular abnormalities.

💡 💡 Clinical Pearl: Monitoring Kidney Function and Potassium

When initiating or increasing the dose of an ACE inhibitor or ARB, clinicians should check serum creatinine and potassium levels within 1 to 2 weeks. A mild increase in creatinine of up to 30% from baseline is acceptable and reflects the hemodynamic unloading of the kidney. If potassium exceeds 5.5 mEq/L or creatinine rises by more than 30%, the dose should be reduced or held, and other classes like Calcium Channel Blockers or Thiazide and Loop Diuretics should be considered.

Avoidance of Dual Therapy

The clinical benefit of blocking the RAAS has led to investigation of whether combining an ACE inhibitor and an ARB (dual therapy) could provide superior cardiovascular and renal protection. The landmark ONTARGET trial compared ramipril monotherapy, telmisartan monotherapy, and their combination in patients at high risk for vascular events. The trial demonstrated that dual therapy did not reduce cardiovascular events or slow renal decline compared to monotherapy. Instead, it significantly increased the rates of hyperkalemia, acute kidney injury, and symptomatic hypotension. Based on these findings, clinical guidelines advise against the concurrent use of ACE inhibitors and ARBs.

💡 Frequently Asked Questions (FAQ)

📚 References & Sources

1. Brenner, B. M., et al. (2001). Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 345(12), 861-869.
2. Yusuf, S., et al. (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine, 358(15), 1547-1559.
3. Lewis, E. J., et al. (2001). Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. New England Journal of Medicine, 345(12), 851-860.